Tricida (NASDAQ:TCDA) Upgraded to Hold by BidaskClub
Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Tricida from a “hold” rating to a “sell” rating in a research note on Wednesday, March 4th. ValuEngine upgraded Tricida from a “sell” rating to a “hold” rating in a research note on Wednesday, March 4th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $49.60.
Shares of TCDA stock traded up $1.89 during trading hours on Thursday, reaching $24.63. The company’s stock had a trading volume of 2,666 shares, compared to its average volume of 333,794. The stock has a market capitalization of $1.13 billion, a P/E ratio of -6.64 and a beta of 0.93. Tricida has a one year low of $18.02 and a one year high of $44.30. The firm’s fifty day simple moving average is $31.31 and its 200 day simple moving average is $34.97. The company has a current ratio of 7.87, a quick ratio of 7.87 and a debt-to-equity ratio of 0.25.
In other Tricida news, CEO Gerrit Klaerner sold 4,000 shares of Tricida stock in a transaction on Monday, March 16th. The stock was sold at an average price of $23.91, for a total transaction of $95,640.00. Following the completion of the transaction, the chief executive officer now owns 563,321 shares in the company, valued at $13,469,005.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Dawn Parsell Otto sold 4,250 shares of Tricida stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $37.04, for a total value of $157,420.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 21,000 shares of company stock valued at $674,995. 66.70% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in TCDA. Meeder Asset Management Inc. purchased a new position in Tricida during the fourth quarter valued at $28,000. Great West Life Assurance Co. Can purchased a new position in shares of Tricida in the fourth quarter worth $50,000. Tower Research Capital LLC TRC purchased a new position in shares of Tricida in the third quarter worth $57,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Tricida by 113.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,973 shares of the company’s stock worth $74,000 after purchasing an additional 1,048 shares during the last quarter. Finally, Quantbot Technologies LP raised its stake in shares of Tricida by 138.8% in the fourth quarter. Quantbot Technologies LP now owns 2,118 shares of the company’s stock worth $79,000 after purchasing an additional 1,231 shares during the last quarter. Institutional investors and hedge funds own 80.22% of the company’s stock.
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Featured Story: What is a Derivative?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.